221

Novo Nordisk A/S won approval to sell a pill version of its obesity shot Wegovy in the US. Novo will start selling the pill, the first of the blockbuster GLP-1 class, in the US in early January. It is approved to help people lose weight or maintain previous weight loss over the long term. Bloomberg’s Amber Tong reports.
Be respectful and constructive. Comments are moderated.

No comments yet.